Skip to main content
Contact Us
Subscribe
E-Edition
65°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Merus N.V. CS
(NQ:
MRUS
)
44.93
+2.96 (+7.05%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Merus N.V. CS
< Previous
1
2
3
4
Next >
Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting
April 24, 2024
From
Merus N.V.
Via
GlobeNewswire
Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024
April 08, 2024
From
Merus N.V.
Via
GlobeNewswire
Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
April 03, 2024
From
Merus N.V.
Via
GlobeNewswire
Expert Ratings for Merus
November 28, 2023
Via
Benzinga
The Latest Analyst Ratings for Merus
October 24, 2023
Via
Benzinga
10 Analysts Have This to Say About Merus
September 14, 2023
Via
Benzinga
Where Merus Stands With Analysts
August 10, 2023
Via
Benzinga
Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers
March 06, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Merus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expression
March 05, 2024
Poster presentation: Monday, April 8, 2024, 9:00 am-12:30 p.m. PT
From
Merus N.V.
Via
GlobeNewswire
Merus to Participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference
March 04, 2024
From
Merus N.V.
Via
GlobeNewswire
Expert Ratings for Merus
July 24, 2023
Via
Benzinga
Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update
February 28, 2024
From
Merus N.V.
Via
GlobeNewswire
Merus to Participate in Upcoming Investor Conferences
January 31, 2024
From
Merus N.V.
Via
GlobeNewswire
Merus Presents Interim Data on MCLA-129 at ESMO Asia Congress 2023
December 02, 2023
MCLA-129 in combination with chemotherapy in 2L+ EGFRm NSCLC planned to initiate 1Q24
From
Merus N.V.
Via
GlobeNewswire
Merus Announces Publication of Abstracts on MCLA-129 for Presentation at ESMO Asia Congress 2023
November 26, 2023
From
Merus N.V.
Via
GlobeNewswire
Merus Announces Financial Results for the Third Quarter 2023 and Provides Business Update
November 02, 2023
From
Merus N.V.
Via
GlobeNewswire
Merus to Participate in Upcoming Investor Conferences
November 01, 2023
From
Merus N.V.
Via
GlobeNewswire
Merus’ Zeno Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ Cancer
October 23, 2023
From
Merus N.V.
Via
GlobeNewswire
Merus Announces Business Update Conference Call
October 15, 2023
From
Merus N.V.
Via
GlobeNewswire
New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review
October 13, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:PYXS),(NASDAQ:AZN),(NYSE:LLY),(NASDAQ:MRUS) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
Merus Announces Abstracts Accepted for Presentation at the ESMO Asia Congress 2023
October 06, 2023
From
Merus N.V.
Via
GlobeNewswire
Pancreatic Cancer Research Gains Momentum Amidst Soaring Young-Onset Cases
September 26, 2023
FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 26, 2023 – USA News Group – The seriousness of pancreatic cancer continues to grow, with increasing alarm since The...
Via
FinancialNewsMedia
AstraZeneca's Tagrisso-Chemo Combo Data In Lung Cancer Sets High Bar For Johnson & Johnson's Cancer Drug: Analyst
September 11, 2023
On Sunday night, AstraZeneca Plc (NASDAQ: AZN) presented the Phase 3 FLAURA2 results evaluating Tagrisso plus chemotherapy versus Tagrisso monotherapy as first-line treatment for patients
Via
Benzinga
Merus to Participate in Upcoming Investor Conferences
August 31, 2023
From
Merus N.V.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 21, 2023
August 21, 2023
Via
Benzinga
Merus Announces Pricing of Public Offering of Common Shares
August 09, 2023
From
Merus N.V.
Via
GlobeNewswire
Merus N.V. Announces Proposed Public Offering of Common Shares
August 09, 2023
From
Merus N.V.
Via
GlobeNewswire
Merus Announces Financial Results for the Second Quarter 2023 and Provides Business Update
August 07, 2023
From
Merus N.V.
Via
GlobeNewswire
Merus Announces Two Clinical Abstracts on Zenocutuzumab (Zeno) in NRG1-fusion (NRG1+) non-small cell lung cancer (NSCLC) and Pancreatic Cancer (PDAC) Selected for Presentation at the ESMO Congress 2023
July 28, 2023
From
Merus N.V.
Via
GlobeNewswire
Zenocutuzumab (Zeno) granted second Breakthrough Therapy Designation by the U.S. Food & Drug Administration
July 05, 2023
From
Merus N.V.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
